The Life Sciences Report

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection
Source: Streetwise Reports  (8/16/17)
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.
More >

'Keep a Close Eye On' This Regenerative Medicine Firm
Source: Streetwise Reports  (8/16/17)
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."
More >

Maxim Raises Target Price of Biotech Company
Source: Streetwise Reports  (8/16/17)
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.
More >

Cell Therapy for Melanoma Impresses in
Phase 2
Source: Streetwise Reports  (8/9/17)
Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst.
More >

Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets
Source: Streetwise Reports  (8/9/17)
With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach.
More >

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover
Source: Streetwise Reports  (8/7/17)
A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8. More >

This Just Changed Everything: Green Profits Are Being Unleashed
Source: Kenneth Ameduri for Streetwise Reports  (8/3/17)
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. More >

Loan Provides Driver for Growth for Medical Device Firm
Source: Streetwise Reports  (8/2/17)
Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth. More >

Canadian Medical Cannabis Provider Expanding into US Market Through RTO
Source: Streetwise Reports  (7/25/17)
A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26. More >

DNA-Based Compound Shuts Down Seasonal Flu in Preclinical Study
Source: Streetwise Reports  (7/19/17)
A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018. More >

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating
Source: Streetwise Reports  (7/19/17)
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company. More >

Biotech with Alzheimer's Focus Makes Progress on Several Fronts
Source: Streetwise Reports  (7/18/17)
In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development. More >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17
Source: Streetwise Reports  (7/13/17)
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. More >

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange
Source: Streetwise Reports  (7/11/17)
A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14. More >

Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial
Source: Streetwise Reports  (7/5/17)
With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.
More >

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story'
Source: Streetwise Reports  (6/29/17)
Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs. More >

With Completion of Offer, Analyst Says This Biotech Stock Could Triple
Source: The Life Sciences Report  (6/28/17)
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside." More >

Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray
Source: The Life Sciences Report  (6/21/17)
A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. More >

Phase 3 Trial for Inovio's VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead
Source: The Life Sciences Report  (6/14/17)
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors. More >

RXi Pharmaceuticals Expands Collaboration with Norwegian Cancer Firm; Gears Up for 2017 Milestones
Source: The Life Sciences Report  (6/7/17)
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts. More >

HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects
Source: The Life Sciences Report  (5/31/17)
A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts. More >

Neuromonitoring Company Founded by Former NFL Quarterback Set to Go Public
Source: The Life Sciences Report  (5/26/17)
Assure Holdings, an intraoperative neuromonitoring company founded by former NFL quarterback Preston Parsons, will begin trading on the TSX Venture Exchange on May 29, under the trading symbol IOM. More >

What Is Chen Buying? Gold, Cobalt, Phosphate and Biotech. . .
Source: Chen Lin for Streetwise Reports  (5/25/17)
With the market in flux, Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? is hedging his bets with investments in a variety of companies in different sectors. More >

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter
Source: The Life Sciences Report  (5/24/17)
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. More >

Small-Caps Rushing to Fill the NASH Treatment Pipeline
Source: The Life Sciences Report  (5/24/17)
NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials. More >